1 / 20

Alena Goldman, MD*, Jeptha P. Curtis, MD † , Yongfei Wang, MS † , William H. Maisel, MD, MPH*. * Beth Israel Deaconess

Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry TM.

coy
Télécharger la présentation

Alena Goldman, MD*, Jeptha P. Curtis, MD † , Yongfei Wang, MS † , William H. Maisel, MD, MPH*. * Beth Israel Deaconess

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR® ICD RegistryTM Alena Goldman, MD*, Jeptha P. Curtis, MD †, Yongfei Wang, MS†, William H. Maisel, MD, MPH*. * Beth Israel Deaconess Medical Center, Boston, MA † Yale-New Haven Hospital, New Haven, CT

  2. Disclosures • Alena Goldman, Jeptha P. Curtis, Yongfei Wang, William H. Maisel: • No Industry Relationships to Disclose

  3. Background • >400K pacemaker and ICD implants a year in North America1. • Perioperative management of anticoagulation in patients undergoing device implant is not firmly established. • Uninterrupted DAP mandated for millions of stent patients2. • Impact on ICD implant complications has not been evaluated. 1 AHA Heart Disease and Stroke Statistics 2001 2 Maisel WH. N Engl J Med. 2007; 356(10):981-4

  4. Background Clinical Implications of Pocket Hematoma • Interruption of anticoagulation • Blood product transfusion • Longer hospital stay • Hematoma evacuation • Increased risk of infection • Risk of thromboembolism if anticoagulation is interrupted

  5. Methods NCDR ICD Registry Database • Developed by ACC/HRS in October of 2005 • Collects information from 1,500 hospitals in US • Required for all Medicare primary prevention ICD implants • 76% of hospitals submit all implants • 88% of all ICD implants in US included • Good representation of “real-world” performance • Goals: • Track outcomes • Determine if findings from major RCTs apply to general population 1 1. S. Hammill, et. al. Heart Rhythm 2008;6:1359-1363

  6. Methods NCDR ICD Registry Database • > 130 data elements collected at the time of the initial ICD implant, device upgrade, and device replacement • Discharge medications recorded – No record of medications at time of implant • Complications at the time of device implantation and prior to hospital discharge are collected • Used data from 4/06-12/08

  7. Study Endpoints (Based on NCDR Complication Definitions) HEMATOMA • Resulting in re-operation or transfusion NON-HEMATOMA BLEEDING • Cardiac Perforation • Cardiac Tamponade • Hemothorax THROMBOEMBOLISM • MI • TIA/CVA • DVT • Peripheral embolus

  8. Patient Characteristics

  9. Patient Characteristics

  10. Baseline Antiplatelet/Anticoagulation Treatment 263,412 ICD Implants Percent of Patients None ASA T/C DAP Warfarin Warfarin Warfarin Warfarin + ASA + T/C + DAP

  11. Effect of AC and AP Therapy on Hematoma Rate P for trend <0.0001 % None ASA T/C DAP Warfarin Warfarin Warfarin Warfarin Overall + ASA + T/C + DAP 263,412 ICD Implants – 2404 Hematomas P for trend for <0.001

  12. Effect of AC and AP Therapy on Non-Hematoma Bleeding Rate % None ASA T/C DAP Warfarin Warfarin Warfarin Warfarin Overall + ASA + T/C + DAP 263,412 ICD Implants – 483 events P for trend =0.004

  13. Effect of AC and AP Therapy on Clotting Rate P for trend <0.0001 % None ASA T/C DAP Warfarin Warfarin Warfarin Warfarin Overall + ASA + T/C + DAP 263,412 ICD Implants - 322 events P for trend for <0.001

  14. Impact of Heart Failure on Complication Rates NYHA Class *P<0.02 compared to NYHA Class I I II III IV Hematoma * * % 0 0.5 1.0 1.5 Non Hematoma Bleeding I II III IV * * % 0 0.1 0.2 0.3 I II III IV Clotting * ^ Percent of total implants * % 0 0.1 0.2 0.3

  15. Impact of Device Type on Complication Rates Device Type * P<0.001 S D B Hematoma * % 0 0.5 1.0 1.5 Non Hematoma Bleeding S D B * % 0 0.5 1.0 1.5 S D B Clotting ^ Percent of total implants * % 0 0.06 0.12 0.18

  16. Impact of Procedure Type on Complication Rates Procedure Type * P<0.01 compared to Gen ∆ Gen. ∆ New Upgrade Hematoma * * % 0 0.5 1.0 1.5 Non Hematoma Bleeding Gen. ∆ New Upgrade * * % 0 0.1 0.2 0.3 Gen. ∆ New Upgrade Clotting * ^ Percent of total implants * % 0 0.1 0.2 0.3

  17. Impact of Hospital Implant Volume on Hematoma Rate Hospital Volume (Implants/yr) 263,412 ICD Implants Low (<59/yr) Middle (60-213/yr) High (>214/yr) P for trend <0.001 * Percent of total implants Hematoma (%)

  18. Limitations • Discharge medications recorded – not necessarily medications at time of procedure • Medication choices not randomized • Potential underreporting of complications

  19. Conclusions • Although anticoagulation and antiplatelet therapy are associated with increased ICD implant hematoma rates, overall rates are low. • DAP, warfarin, and triple therapy are associated with progressively higher bleeding rates.

  20. Conclusions • Worsening NYHA class, increasing ICD device complexity, procedure type, and lower hospital implant volume are independently associated with increased rates of hematoma, non-hematoma bleeding, and thromboembolic events. • These data should be considered when selecting patients for ICD implant.

More Related